Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4157-4163

  Hiraga, Toru ^a,b   Kizaka Kondoh, Shinae ^c   Hirota, Kiichi ^d   Hiraoka, Masahiro ^c   Yoneda, Toshiyuki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b MATSUMOTO DENTAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; OXYGEN; PROTEIN TOP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CASPASE 3; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; MICE; MICE, INBRED C3H; MICE, NUDE; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 34249340478     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2355     Document Type: Article

References (40)

1. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
2. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003;94:1021-8.
3. Harris AL. Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2002;2:38-47.
4. Vaupel S, Briest S, Hockel M. Hypoxia in breast cancer: pathogenesis, characterization and biological/ therapeutic implications. Wien Med Wochenschr 2002; 152:334-42.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
6. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003;278:19575-8.
7. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14.
8. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59:5830-5.
9. Gruber G, Greiner RH, Hlushchuk R, et al. Hypoxia-inducible factor 1α in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 2004;6:R191-8.
10. Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1α is associated with and unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7.
11. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2: 584-93.
12. Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 2002;62:2013-8.
13. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72.
14. Kelly BD, Hackett SF, Hirota K, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003;93:1074-81.
15. Kasuno K, Takabuchi S, Fukuda K, et al. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 2004;279:2550-8.
16. Yeo E-J, Chun Y-S, Cho Y-S, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
17. Ichida F, Nishimura R, Hata K, et al. Reciprocal roles of Msx2 in regulation of osteoblast and adipocyte differentiation. J Biol Chem 2004;279:34015-22.
18. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor β enhances bone metastases in breast cancer. Cancer Res 2006;66: 2067-73.
19. Ito M, Amizuka N, Tanaka S, et al. Ultrastructural and cytobiological studies on possible interactions between PTHrP-secreting tumor cells, stromal cells, and bone cells. J Bone Miner Metab 2003;21:353-62.
20. Miyake S, Makimura M, Kanegae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci U S A 1996;93:1320-4.
21. Asoh S, Ohsawa I, Mori T, et al. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci U S A 2002;99:17107-12.
22. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1a in perinecrotic regions of solid tumors. Cancer Res 2005;65: 7259-66.
23. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
24. Sasaki A, Alcalde RE, Nishiyama A, et al. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res 1998;58:462-7.
25. Weber MH, Lee J, Orr FW. The effects of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol 2002;20:299-303.
26. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94.
27. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005;106:3160-5.
28. Park JH, Park BH, Kim HK, Park TS, Baek HS. Hypoxia decreases Runx2/Cbfa1 expression in human osteoblast-like cells. Mol Cell Endocrinol 2002;192: 197-203.
29. Salim A, Nacamuli RP, Morgan EF, Giaccia AJ, Longaker MT. Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts. J Biol Chem 2004;279:40007-16.
30. Tuncay OC, Ho D, Barker MK. Oxygen tension regulates osteoblast function. Am J Orthod Dentofacial Orthop 1994;105:457-63.
31. Warren SM, Steinbrech DS, Mehrara BJ, et al. Hypoxia regulates osteoblast gene expression. J Surg Res 2001;99: 147-55.
32. Arnett TR, Gibbons DC, Utting JC, et al. Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol 2003;196:2-8.
33. Fukuoka H, Aoyama M, Miyazawa K, Asai K, Goto S. Hypoxic stress enhances osteoclast differentiation via increasing IGF2 production by non-osteoclastic cells. Biochem Biophys Res Commun 2005;328:885-94.
34. Frick KK, Bushinsky DA. Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclooxygenase-dependent mechanism. J Bone Miner Res 2003;18:1317-25.
35. Komarova SV, Pereverzev A, Shum JW, Sims SM, Dixon SJ. Convergent signaling by acidosis and receptor activator of NF-κB ligand (RANKL) on the calcium/ calcineurin/NFAT pathway in osteoclasts. Proc Natl Acad Sci U S A 2005;102:2643-8.
36. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901.
37. 2 study. Cancer 2000; 89:2018-24.
38. 2 study. Am J Clin Oncol 2001;24:458-61.
39. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005;65:8274-85.
40. Masuda H, Fukabori Y, Nakano K, Takezawa Y, Suzuki T, Yamanaka H. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003;54:268-74.